Kemal Karaagac/LinkedIn
Oct 3, 2026, 05:52
Kemal Karaagac: When Vitamin K Antagonists Remain Essential in Cardiac Care
Kemal Karaagac, Cardiologist at Cihangir Hospital, shared a post on X about a recent article by Eva Kempers et al., published in Heart, adding:
“VKAs remain essential when DOACs are unsuitable or their benefit is uncertain, including mechanical valves, AF with moderate-to-severe mitral stenosis, thrombi, and some frail older patients. Despite DOAC advances, VKA therapy remains vital in selected patients.”
Title: Timeless therapeutics: cardiac indications for vitamin K antagonists in clinical practice
Authors: Eva K. Kempers, Melanie Jacqueline J. Acampo-de Jong, Hugo ten Cate, Raffaele De Caterina, Marieke J. H. A. Kruip
Stay updated on all scientific advances with Hemostasis Today.
Anticoagulation
Atrial Fibrillation
cardiac thrombi
Cardiology
DOACs
Eva K Kempers
Frailty
Heart
Hemostasis News
Hemostasis Today
Hugo ten Cate
Kemal Karaagac
Marieke J.H.A. Kruip
Mechanical Heart Valves
Melanie Jacqueline J. Acampo-de Jong
Mitral Stenosis
Raffaele De Caterina
Vitamin K antagonists
VKAs
-
Oct 16, 2026, 13:10Emanuel Sueldo: CAHT 2026 Celebrates Scientific Progress and Team Achievements
-
Oct 16, 2026, 13:05Maha Othman: Queen’s Health Sciences Advances CAT Risk Models and Pediatric ISTH-BAT Cut-Offs
-
Oct 16, 2026, 13:03Thrombosis Awareness Must Lead to Timely Action – Roche
-
Oct 16, 2026, 12:49Wolfgang Miesbach: 5-Year CBDR Data Confirms Emicizumab Safety and Efficacy in Hemophilia A
-
Oct 16, 2026, 12:40Edward Lee Carter: How Factor XI Inhibition Could Transform Anticoagulation Therapy
-
Oct 16, 2026, 12:40Marc Carrier: Looking Ahead to ISTH 2027 in Vancouver
-
Oct 16, 2026, 12:30Bob Lempke: How One Blood Donation Can Save Up to Three Lives
-
Oct 16, 2026, 12:30Why VWF Therapies Belong on the EU Critical Medicines List – EHC
-
Oct 16, 2026, 12:17Exploring Endothelial Cells, Genetic Fate Mapping, and Revascularization – ISTH